TACI, ELISA Kit

Tumor necrosis factor receptor superfamily member 13B; Transmembrane activator and CAML interactor; CD267

For Research Use Only. Not for use in diagnostic procedures.

The OmniKine Human TACI ELISA is capable of recognizing both recombinant and naturally produced Human TACI proteins. The antigens listed below were tested at 50 ng/ml and did not exhibit significant cross reactivity or interference.
Human: 4-1BBL, 4-1BBR, AITRL, BAFF, BAFF-R, BCMA, CD-40L, Fas-L, Fas-R, OPG, sRANK-L, sRANK-R, TNF-alpha, TNF-beta, sTNF-R1, sTNF-R2, sTRAIL, sTRAIL-R1, sTRAIL-R2, TWEAK, TWEAK-R

12 x 8-Well Microstrips

Store at 4 degree C for 6 months.

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of TACI elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS9501889 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the TACI, ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing TACI. The ELISA analytical biochemical technique of the MBS9501889 kit is based on TACI antibody-TACI antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect TACI antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, TACI. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

The OmniKine Human TACI ELISA Kit allows for the detection and quantification of endogenous levels of natural and/or recombinant Human TACI proteins within the range of 16-2000 pg/ml.

19,865 Da

TNF receptor superfamily member 13B

tumor necrosis factor receptor superfamily member 13B

Tumor necrosis factor receptor superfamily member 13B

TACI  [Similar Products]

The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]

TNFRSF13B: Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T- cell function and the regulation of humoral immunity. Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2). CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2). Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell cycle regulation; Membrane protein, integral; Receptor, misc.

Chromosomal Location of Human Ortholog: 17p11.2

Cellular Component: external side of plasma membrane; integral component of plasma membrane; plasma membrane

Molecular Function: protein binding; receptor activity

Biological Process: adaptive immune response; B cell homeostasis; cell surface receptor signaling pathway; hemopoietic progenitor cell differentiation; negative regulation of B cell proliferation; tumor necrosis factor-mediated signaling pathway

Disease: Immunodeficiency, Common Variable, 2; Immunoglobulin A Deficiency 2

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.